Evercore ISI analyst Cory Kasimov initiated coverage of SpringWorks Therapeutics (SWTX) with an Outperform rating and $60 price target SpringWorks looks “well positioned” based on its first-in-class approved therapy for a rare oncology indication, Ogsiveo, the first and only FDA approved tx for desmoid tumors, and “the near-term potential to become a two-product story” with Mirdametinib, for which the firm sees a potential Q1 of 2025 approval, the analyst tells investors. Shares bouncing post a slight Q3 miss suggests “this is an attractive entry point with solid, underlying market dynamics carrying greater weight,” the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SWTX:
- Biotech Alert: Searches spiking for these stocks today
- Immunome price target lowered to $21 from $23 at Piper Sandler
- SpringWorks Therapeutics Q3 2024 Results Overview
- SpringWorks price target lowered to $74 from $76 at H.C. Wainwright
- SpringWorks Therapeutics reports Q3 EPS (72c), consensus (75c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
